Glaxo Wellcome is developing the NK1 antagonist
GR-205171 for the potential treatment of
chemotherapy- and
radiotherapy-induced
emesis, post-operative
nausea and
emesis, and
migraine. Phase II trials have commenced for both these indications.
GR-205171 has a similar affinity for the NK1 receptor as
CP-99994 [176071,193105]. Glaxo anticipates NDA and MAA filings in 2000 [244813]. A trial of
GR-205171 in combination with
ondansetron demonstrated the combination to be highly effective in the prevention of acute
cisplatin-induced
emesis. Complete responses were seen in all patients receiving high-dose
GR-205171 plus
ondansetron. The combination provided complete control of
nausea in 16 h in 10 out of 12 patients [289484]. The compound has an ED90 value of 0.03 mg/kg against radiation-induced
emesis in the ferret [207316].
GR-205171 is also active against adjuvant-induced inflammatory
pain in the rat and may be of potential use in the treatment of chronic inflammatory
pain.